Pinals R S, Kaplan S B, Lawson J G, Hepburn B
Arthritis Rheum. 1986 Dec;29(12):1427-34. doi: 10.1002/art.1780291202.
Sulfasalazine (SSZ), 3 gm daily, was compared with placebo for treatment of rheumatoid arthritis, in a 15-week randomized, parallel, double-blind trial. Joint tenderness and swelling, morning stiffness, grip strength, and pain score all showed significantly more improvement with SSZ than with placebo. Adverse effects, particularly gastrointestinal reactions, led to withdrawal from the study of 28% of the patients who had been receiving SSZ, but these effects were all readily reversible and not life-threatening. These results confirm previous findings that suppression of rheumatoid synovitis may be induced by SSZ, within 2 months after full maintenance doses are reached.
在一项为期15周的随机、平行、双盲试验中，将每日3克的柳氮磺胺吡啶（SSZ）与安慰剂用于类风湿性关节炎的治疗进行比较。与安慰剂相比，SSZ在关节压痛和肿胀、晨僵、握力及疼痛评分方面均显示出更显著的改善。不良反应，尤其是胃肠道反应，导致28%接受SSZ治疗的患者退出研究，但这些影响均易于逆转且无生命危险。这些结果证实了先前的研究发现，即达到完全维持剂量后2个月内，SSZ可诱导类风湿性滑膜炎得到抑制。
